Saccade, a Y Combinator startup, is building an eye-tracking test for early Alzheimer's risk, and no validation results were found in the materials reviewed. It is entering a field where the diagnostic bar moved this summer: the FDA cleared blood tests from Roche and C2N within days of each other in August 2026, which may mean a new screening tool will be measured against tests that are already cleared, not merely the status quo.
What Saccade Says It Does
The company appears in Y Combinator's company directory. Shreyas Bhardwaj, its founder and chief executive, said in the company's YC launch copy, which is undated: "We're live in San Francisco clinics, testing people in their 30s and older for early risk indicators."
Whether that availability still holds could not be confirmed. In the materials reviewed, Saccade did not disclose funding, customers or clinical results on its own website or YC page. Public records show an SBIR award associated with the company.
A Crowded Field of Cleared Competitors
The newly cleared blood tests are aimed at a different patient. Roche announced FDA clearance of its Elecsys pTau217 assay on August 24, 2026, for symptomatic adults 55 and older in primary and specialty care. The test is not cleared for population screening, and Roche said that predicting future dementia is not an established use of it.
C2N's PrecivityAD2 followed, with clearance announced August 20, 2026, for adults 40 and older who show cognitive signs or symptoms.
Distribution is shifting as well. Quest Diagnostics said on August 24 that it plans to launch the Roche assay in the fourth quarter of 2026 and add it to future panels in 2027. A plan is not a completed rollout, and the announcement alone does not show one. Roche also cited more than 4,500 cobas laboratory instruments in the United States, though that figure reflects installed base rather than the number actually running Alzheimer's assays.
Evidence Builds Behind Blood Tests
Real-world data is accumulating. An interim study presented at the Alzheimer's Association International Conference (AAIC) on July 14, 2026, showed improved diagnostic accuracy among physicians and changes in how patients were managed. It is conference-stage evidence, and should be read that way.
"A negative result helped primary care physicians confidently rule out Alzheimer's and look for other causes of the symptoms," said Sebastian Palmqvist, a neurologist and associate professor at Lund University.
Demand for broader use is a separate question. Andrea Russell, an assistant professor at Northwestern University Feinberg School of Medicine, said in an April 15, 2026, announcement: "These tests aren't ready for widespread use, but they soon could be."
Other Eye-Based Approaches
Eye-based screening already has a better-documented rival. RetiSpec, a retinal-imaging company working with the University of Minnesota, was the subject of a university report published November 4, 2026. The report described an October 29 symposium, second-generation cameras and multisite clinical trials. It was not an FDA clearance announcement. A PR Newswire headline said RetiSpec closed $10 million to advance commercialization of its AI-driven eye test.
Swati More, a University of Minnesota professor and co-inventor of the technology, said at the symposium: "What is needed is diagnosis at a stage where therapies will have the best chance to work."
Separately, Stanford Medicine reported on November 4 an experimental brain-connectivity risk score. It was applied to more than 1,300 cognitively unimpaired adults aged 55 to 70, with follow-up of up to 12 years. It is not a diagnostic test.
The Unanswered Question for Presymptomatic Testing
Saccade's pitch to younger, asymptomatic users sits where the evidence is thinnest. Roche's clearance covers symptomatic adults, and the Stanford score remains experimental. Whether testing people before symptoms appear changes outcomes is still being studied.
Eli Lilly lists its TRAILBLAZER-ALZ 3 trial of donanemab in presymptomatic patients as phase III, with 2,996 participants and an estimated completion date of November 2027. Those results are still future evidence.
For Saccade, the next milestone is data. No validation results for its test were found in the materials reviewed, in a market where competitors hold FDA clearances.
